Nanoparticle-Based Cpg-Oligonucleotide Therapy For Treating Allergic Asthma

Givens, Brittany E.; Geary, Sean M.; Salem, Aliasger K.

doi:10.2217/imt-2017-0142

Cited by 21 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jalur pensinyalan yang dimediasi oleh chemokine dan reseptor chemokine CC 3 (CCR3) penting untuk penemuan obat asma. 61,62,63 Para peneliti mengembangkan peptida NP CCR3 inhibitor (R321) baru yang dapat menghambat transduksi sinyal reseptor CCR3. Eosinofil di saluran napas, paru-paru, dan darah dicegah dari akumulasi pada tikus asma sementara R321 juga mencegah awal hiperesponsivitas saluran napas pada tikus model asma.…”

Section: Nanoteknologi Dalam Pengembangan Terapi Asmaunclassified

Pendekatan Multiperspektif Dalam Manajemen Penyakit Asma

Anurogo

2022

MEDICINUS

View full text Add to dashboard Cite

show abstract

Section: Nanoteknologi Dalam Pengembangan Terapi Asmaunclassified

Pendekatan Multiperspektif Dalam Manajemen Penyakit Asma

Anurogo

2022

MEDICINUS

View full text Add to dashboard Cite

show abstract

“…CpG ODN being linked directly onto the allergen has displayed great promise as a therapeutic and prophylactic system for allergic diseases in preclinical studies [66]. Moreover, delivering CpG ODN on nanostructures that have the potential to serve as platforms for several allergens have performed similarly well in preclinical and even clinical studies [67,68].…”

Section: Cpg Oligodeoxynucleotidementioning

confidence: 99%

Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research

2020

View full text Add to dashboard Cite

The increasing prevalence of allergic diseases demands efficient therapeutic strategies for their mitigation. Allergen-specific immunotherapy (AIT) is the only causal rather than symptomatic treatment method available for allergy. Currently, AIT is being administered using immune response modifiers or adjuvants. Adjuvants aid in the induction of a vigorous and long-lasting immune response, thereby improving the efficiency of AIT. The successful development of a novel adjuvant requires a thorough understanding of the conventional and novel adjuvants under development. Thus, this review discusses the potentials and challenges of these adjuvants and their mechanism of action. Vaccine development based on nanoparticles is a promising strategy for AIT, due to their inherent physicochemical properties, along with their ease of production and ability to stimulate innate immunity. Although nanoparticles have provided promising results as an adjuvant for AIT in in vivo studies, a deeper insight into the interaction of nanoparticle–allergen complexes with the immune system is necessary. This review focuses on the methods of harnessing the adjuvant effect of nanoparticles by detailing the molecular mechanisms underlying the immune response, which includes allergen uptake, processing, presentation, and induction of T cell differentiation.

show abstract

“…CpG-ODNs are recognized by the pathogen recognition receptor TLR-9 on B-cells, dendritic cells, and other cell types and promote T H 1 and Treg responses [39]. Although a relatively old concept, CpG-ODNs have emerged recently as adjuvants in immunotherapy and have been used for different types of immunotherapies [40][41][42].…”

Section: Immunostimulatory Sequencesmentioning

confidence: 99%

Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response

Zubeldía

Ferrer

Dávila

et al. 2019

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is the only treatment that can affect the natural course of allergic diseases such as allergic asthma, allergic rhinitis, and IgE-mediated food allergy. Adjuvants are used to induce a quicker, more potent, and longer-lasting immune response. Only 4 compounds are used as adjuvants in currently marketed AIT products: aluminum hydroxide, calcium phosphate, microcrystalline tyrosine (MCT), and monophosphoryl lipid A (MPL). The first 3 adjuvants are delivery systems with a depot effect, although they may also have immunomodulatory properties. These first-generation adjuvants are still widely used, especially aluminum hydroxide. However, aluminum is subject to limitations. MCT is the depot formulation of L-tyrosine; it enhances IgG production without inducing a significant increase in IgE, is biodegradable, and has good local and systemic tolerability. In turn, MPL is an immunostimulatory agent that is the only second-generation adjuvant currently used for AIT. In addition, multiple adjuvants are currently being studied, including immunostimulatory sequences (ISSs), nanoparticles (liposomes, virus-like particles, and biodegradable polymers), and phosphatidylserine derivatives. In a murine model of allergic bronchial inflammation by sensitization to olive pollen, the specific IgE level was significantly higher in sensitized mice treated with olive pollen and aluminum hydroxide. However, specific IgE levels were significantly reduced and bronchial hyperreactivity significantly improved in sensitized mice treated with olive pollen and bacterial derivatives (MPL or ISSs).

show abstract

Nanoparticle-Based Cpg-Oligonucleotide Therapy For Treating Allergic Asthma

Cited by 21 publications

References 67 publications

Pendekatan Multiperspektif Dalam Manajemen Penyakit Asma

Pendekatan Multiperspektif Dalam Manajemen Penyakit Asma

Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research

Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response

Contact Info

Product

Resources

About